Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 22,004 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Healthy Adults
Interventions: MIB-725; Drug
Lead sponsor: Metro International Biotech, LLC; Industry
Eligibility: 19 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer Metastatic Disease
Interventions: Hypocaloric anti-inflammatory diet; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Epidiferphane, Taxane Chemotherapy; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Dystonia, Drug Induced Dystonia, Parkinson Disease, Essential Tremor, Dyskinesias, Myoclonus, Tic Disorders, Torticollis, Ulnar Nerve Entrapment, Temporomandibular Joint Disorders, Dysphonia
Interventions: DystoniaNet-based diagnosis of isolated dystonia; Diagnostic Test
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postpartum Depression (PPD), Self-Efficacy, Parental Anxiety, Engagement, Patient, Usability, Length of Stay
Interventions: VoiceLove mobile phone application; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 2
Interventions: iPATH implementation approach; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 119,680 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Stanford, California • Boston, Massachusetts • Columbus, Ohio

Conditions: Advanced Cancer, Metastatic Cancer
Interventions: Financial Hardship Screening, Enhanced Usual Care; Other
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 21 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Phoenix, Arizona • Concord, New Hampshire • Manchester, New Hampshire + 3 more

Conditions: Intracranial Pressure Increase
Interventions: Video ophthalmoscope; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 4 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
Interventions: Subcutaneous Blinatumomab; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Parkinson's Disease (PD)
Interventions: adaptive DBS (aDBS); Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Centella asiatica product, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 60 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Spinal Fusion, Chronic Lower Back Pain
Interventions: Laser Diode Brace, Sham Laser Diode Brace; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Physical Therapy, Total Joint Arthroplasty, Same-day Discharge
Interventions: Novel same-day discharge protocol after total joint arthroplasty, Conventional postoperative physical therapy clearance; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 90 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Endometriosis
Interventions: NettleEndo, Sham NettleEndo Device; Device
Lead sponsor: Samphire Group, Inc.; Industry
Eligibility: 22 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anxiety, Memory, Epilepsy
Interventions: CAMERA (Context-Aware Multimodal Ecological Research and Assessment); Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Leptomeningeal Cancer
Interventions: Neurological Assessment; Other
Lead sponsor: University of Zurich; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peripheral Artery Disease (PAD)
Interventions: Not listed
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Arlington, Texas

Conditions: Pancreatic Neoplasm
Interventions: Chemical Ablation, Computed Tomography, Electronic Health Record Review, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Endoscopic Ultrasound-Guided Radiofrequency Ablation, Magnetic Resonance Cholangiopancreatography, Magnetic Resonance Imaging; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pain Crisis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 90 Years
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Complex Regional Pain Syndrome I (CRPS I)
Interventions: Not listed
Lead sponsor: Ambros Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: ICU Delirium, Critical Illness
Interventions: Ketone monoester, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glioma, Malignant, IDH Mutation
Interventions: DSP-0390; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Blasts 10 Percent or More of Peripheral Blood White Cells, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: Cladribine, Cytarabine, Gilteritinib, Idarubicin, Laboratory Biomarker Analysis, Midostaurin, Venetoclax; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gynecologic Cancers
Interventions: Starting the Conversation, Sexual Health Resources; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

Role of Race in Nutritional Approach in Men on ADT

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia

NICU Utilization of Remote Voice Technology to Improve mateRnal Experience (NURTURE)

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)

Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer

Non-Invasive and Non-Contact Intracranial Pressure Waveform Recording Using Dynamic Video Ophthalmoscopy

Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)

Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in Parkinson Disease

Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

Photobiomodulation for Lower Back Pain Post Spinal Fusion and Decompression Surgery

Is Physical Therapy Clearance Before Arthroplasty Home Discharge Necessary?

Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups

Prediction of Anxiety and Memory State

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis

Using Near-Infrared Light to Better Understand Peripheral Artery Disease

Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study

Natural History of Sickle Cell Disease

CRPS-RISE Outcomes Registry

Exogenous Ketone Supplementation in ICU Delirium

Window of Opportunity Study of DSP-0390 in Gliomas

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Communication About Sexual Health in Gynecologic Cancer